Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder

[1]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[2]  S. Marder,et al.  The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. , 1997, The Journal of clinical psychiatry.

[3]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[4]  R. Conley,et al.  Rehospitalization Risk with Second-Generation and Depot Antipsychotics , 2003, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[5]  D. Revicki,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial , 1999, Quality of Life Research.

[6]  M. Singh,et al.  The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance. , 1989, Archives of general psychiatry.

[7]  J. Csernansky,et al.  A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. , 2002, The New England journal of medicine.

[8]  Z. Cernovsky,et al.  Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study , 2002, Schizophrenia Research.

[9]  D M Steinwachs,et al.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. , 1998, Schizophrenia bulletin.

[10]  Howard B. Lee,et al.  Foundations of Behavioral Research , 1973 .

[11]  G. Oster,et al.  The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. , 1999, The Journal of clinical psychiatry.

[12]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[13]  C. Correll,et al.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. , 2004, The American journal of psychiatry.

[14]  R. Jennrich,et al.  Unbalanced repeated-measures models with structured covariance matrices. , 1986, Biometrics.

[15]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[16]  John G Csernansky,et al.  Relapse and Rehospitalisation Rates in Patients with Schizophrenia , 2002, CNS drugs.

[17]  G. Stimmel.  Benzodiazepines in Schizophrenia , 1996, Pharmacotherapy.

[18]  D M Steinwachs,et al.  Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. , 1998, Schizophrenia bulletin.

[19]  I. Glick,et al.  Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders , 2002, International clinical psychopharmacology.

[20]  L. Linn,et al.  Chronic mental patients: the quality of life issue. , 1982, The American journal of psychiatry.

[21]  J. Ware,et al.  What information do consumers want and how will they use it? , 1995, Medical care.

[22]  J. Frost,et al.  Clinical research techniques in tardive dyskinesia. , 1977, The American journal of psychiatry.

[23]  N. Keks.  Impact of newer antipsychotics on outcomes in schizophrenia. , 1997, Clinical therapeutics.

[24]  D. Revicki.  Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia , 1999, Schizophrenia Research.

[25]  J. Bobes,et al.  Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study , 2003, European Neuropsychopharmacology.

[26]  Guttmacher Ms.  PHENOTHIAZINE TREATMENT IN ACUTE SCHIZOPHRENIA; EFFECTIVENESS: THE NATIONAL INSTITUTE OF MENTAL HEALTH PSYCHOPHARMACOLOGY SERVICE CENTER COLLABORATIVE STUDY GROUP. , 1964 .

[27]  W H Rogers,et al.  Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. , 1995, Medical care.